The drug maker announced it’s cutting the price of its most commonly-used insulins by 70%, and capping patients’ out-of-pocket cost at $35 at certain participating pharmacies.

Many people with diabetes who can’t afford the insulin they need to stay alive are turning to social media for help.

In other developed countries, affordability is far less of an issue.

Lawmakers have been critical of big pharma's pricing structures.